Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need.
The business
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Small Caps Research
No research on Radiopharm Theranostics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise RAD based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Radiopharm Theranostics Reports Positive Results from RAD204 and RAD101 Trials
Radiopharm Theranostics reports durable partial response for RAD204 in Phase 1; RAD101 Phase 2b brain mets shows 93% MRI-PET concordance, 86% sensitivity.
Radiopharm Theranostics Doses First Patient in RV-01 Phase 1/2a Trial for Aggressive Cancers
RAD doses first patient in RV-01 Phase 1/2a trial for aggressive cancers, a 177Lu-radiotherapeutic targeting B7-H3, to define dose for future studies.
Radiopharm Theranostics Granted Ethics Approval for RAD402 Phase 1 Trial to Treat Advanced Prostate Cancer
Radiopharm Theranostics (ASX: RAD) has received Bellberry human research ethics committee approval in Australia for a Phase 1 first in-human clinical trial of RAD402 for the treatment of metastatic or locally-advanced prostate cancer.
Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset
Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers. The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.